- Home
- TXMD vs NVNO Comparison
TXMD vs NVNO Comparison
Compare TXMD & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- NVNO
- Stock Information
- Founded
- TXMD 2008
- NVNO 1987
- Country
- TXMD United States
- NVNO United States
- Employees
- TXMD N/A
- NVNO N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- TXMD Health Care
- NVNO Health Care
- Exchange
- TXMD Nasdaq
- NVNO Nasdaq
- Market Cap
- TXMD 17.6M
- NVNO 16.7M
- IPO Year
- TXMD N/A
- NVNO N/A
- Fundamental
- Price
- TXMD $1.63
- NVNO $0.36
- Analyst Decision
- TXMD
- NVNO
- Analyst Count
- TXMD 0
- NVNO 0
- Target Price
- TXMD N/A
- NVNO N/A
- AVG Volume (30 Days)
- TXMD 166.8K
- NVNO 829.5K
- Earning Date
- TXMD 11-12-2025
- NVNO 10-31-2025
- Dividend Yield
- TXMD N/A
- NVNO N/A
- EPS Growth
- TXMD N/A
- NVNO N/A
- EPS
- TXMD 0.03
- NVNO N/A
- Revenue
- TXMD $2,796,000.00
- NVNO N/A
- Revenue This Year
- TXMD $427.09
- NVNO N/A
- Revenue Next Year
- TXMD N/A
- NVNO N/A
- P/E Ratio
- TXMD $259.70
- NVNO N/A
- Revenue Growth
- TXMD 75.19
- NVNO N/A
- 52 Week Low
- TXMD $0.70
- NVNO $0.30
- 52 Week High
- TXMD $2.44
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- TXMD 55.64
- NVNO 25.38
- Support Level
- TXMD $1.55
- NVNO $0.30
- Resistance Level
- TXMD $2.08
- NVNO $0.35
- Average True Range (ATR)
- TXMD 0.28
- NVNO 0.05
- MACD
- TXMD 0.01
- NVNO -0.01
- Stochastic Oscillator
- TXMD 48.69
- NVNO 15.44
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.